Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1741-7015
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease ; volume:10 ; number:1 ; day:8 ; month:11 ; year:2012 ; pages:1-10 ; date:12.2012
BMC medicine ; 10, Heft 1 (8.11.2012), 1-10, 12.2012
- Creator
-
Bruera, Gemma
- Contributor
-
Cannita, Katia
Di Giacomo, Daniela
Lamy, Aude
Troncone, Giancarlo
Dal Mas, Antonella
Coletti, Gino
Frébourg, Thierry
Sabourin, Jean Christophe
Tosi, Mario
Ficorella, Corrado
Ricevuto, Enrico
SpringerLink (Online service)
- DOI
-
10.1186/1741-7015-10-135
- URN
-
urn:nbn:de:1111-2016072946793
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bruera, Gemma
- Cannita, Katia
- Di Giacomo, Daniela
- Lamy, Aude
- Troncone, Giancarlo
- Dal Mas, Antonella
- Coletti, Gino
- Frébourg, Thierry
- Sabourin, Jean Christophe
- Tosi, Mario
- Ficorella, Corrado
- Ricevuto, Enrico
- SpringerLink (Online service)
Other Objects (12)
Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer
Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories
Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer
Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories
Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer